Advancing U.S.-based cGMP manufacturing to support clinical and future commercial objectives of a novel siRNA therapy ...
Company reports >25% oral bioavailability in swine and non-human primatesProgressing multiple collaborations toward partnershipsSAN DIEGO, ...
Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...
Amgen (NasdaqGS:AMGN) released Phase 3 data for a subcutaneous, on-body injector version of TEPEZZA for Thyroid Eye Disease.
Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results